Ticker

No recent analyst price targets found for PPCB.

Latest News for PPCB

Propanc Biopharma Signs MOU with Avance Clinical Pty Ltd

MELBOURNE, Australia, July 07, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has signed a Memorandum of Understanding (MOU) with Avance Clinical Pty Ltd. The MOU sets out the shared intent of Propanc and Avance to work…

GlobeNewsWire • Jul 7, 2026
Propanc Biopharma Initiates $5.0 Million Share Repurchase Program

MELBOURNE, Australia, July 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has initiated a share repurchase program authorizing the Company to repurchase a first tranche of up to $500,000 over the next 30-day period.…

GlobeNewsWire • Jul 2, 2026
Propanc Biopharma's CEO Tours European CDMO & Plans for GMP Production of PRP for Phase 1b, FIH Study

MELBOURNE, Australia, June 16, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc's Chief Executive Officer, toured the GMP (Good Manufacturing Practice) facility of the European CDMO…

GlobeNewsWire • Jun 16, 2026
Propanc Biopharma Authorizes $5.0 Million Share Repurchase Program

MELBOURNE, Australia, June 11, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced it has approved a share repurchase program authorizing the Company to repurchase up to $5.0 million of its common stock. “With our recent…

GlobeNewsWire • Jun 11, 2026
Propanc Biopharma's CEO Attends Keynote Address, “Rejuvenation and Health: Science for an Ageing Society,” at the University of Granada, Spain

MELBOURNE, Australia, June 02, 2026 (GLOBE NEWSWIRE) -- Propanc Biopharma, Inc. (Nasdaq: PPCB) (“Propanc” or the “Company”), a biopharmaceutical company focused on developing novel treatments for chronic diseases, including recurrent and metastatic cancer, today announced that Mr. James Nathanielsz, Propanc's Chief Executive Officer, attended a keynote address, “Rejuvenation and Health: Science for an Ageing…

GlobeNewsWire • Jun 2, 2026

🧮 Earnings Move Analyzer

Insider Trading

Insider Trading

NameRoleDateTypeSharesPriceFormLink

No Senate trades found for PPCB.

No House trades found for PPCB.

Options Chain

Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.

Scroll to Top